umbralisib
Sign in to saveAlso known as RP-5264, TGR-1202, RP5264, TGR1202
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 571.183124
- Has use
- medication
Show 5 more facts
- chemical formula
- C₃₁H₂₄F₃N₅O₃
- canonical SMILES
- CC(C)OC1=C(C=C(C=C1)C2=NN(C3=C2C(=NC=N3)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F
- isomeric SMILES
- C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=C(C(=N4)C6=CC(=C(C=C6)OC(C)C)F)C(=NC=N5)N
- physically interacts with
- ABL proto-oncogene 1, non-receptor tyrosine kinase
- Commons category
- Umbralisib
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- Legal status
- References
- External links
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
Umbralisib is a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon.
Excerpted from Wikipedia’s “umbralisib” article, available under the CC BY-SA 4.0 licence.